Volume | 1,200,332 |
|
|||||
News | - | ||||||
Day High | 2.07 | Low High |
|||||
Day Low | 1.87 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ATAI Life Sciences NV | ATAI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.87 | 1.87 | 2.07 | 1.97 | 1.87 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,342 | 1,200,332 | $ 2.00 | $ 2,396,244 | - | 1.025 - 2.85 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:23:01 | 7 | $ 1.97 | USD |
ATAI Life Sciences NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
327.04M | 166.01M | - | 314k | -40.22M | -0.24 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ATAI Life Sciences NV News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATAI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.07 | 2.205 | 1.80 | 1.96 | 1,138,451 | -0.11 | -5.31% |
1 Month | 1.70 | 2.85 | 1.67 | 2.28 | 2,538,621 | 0.26 | 15.29% |
3 Months | 1.96 | 2.85 | 1.58 | 2.08 | 1,721,284 | 0.00 | 0.00% |
6 Months | 1.28 | 2.85 | 1.025 | 1.84 | 1,422,026 | 0.68 | 53.13% |
1 Year | 2.13 | 2.85 | 1.025 | 1.82 | 1,099,302 | -0.17 | -7.98% |
3 Years | 21.00 | 22.91 | 1.025 | 3.96 | 978,269 | -19.04 | -90.67% |
5 Years | 2.30 | 22.91 | 1.025 | 3.90 | 867,467 | -0.34 | -14.78% |
ATAI Life Sciences NV Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |